Teva to Host Conference Call to Discuss First Quarter 2023 Financial Results at 8 a.m. ET on May 10, 2023

TEL AVIV, Israel–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. … [Read more…]

MEI Pharma Announces 1-for-20 Reverse Stock Split

SAN DIEGO–(BUSINESS WIRE)–MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that its board of directors approved a 1-for-20 reverse stock split. The Company’s common stock will open for trading on the Nasdaq Capital Market on Monday, April 17, 2023 on a split-adjusted basis under the … [Read more…]

Rapid Dose Announces Filing of Corrective Disclosure

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE) announces that further to the review by the Ontario Securities Commission (“OSC”) of the Company’s continuous disclosure record, and a subsequent request from staff of the OSC in connection therewith, the Company has filed corrective disclosure with respect to the following documents: management’s … [Read more…]

China Must Ensure Safety Is Paramount in Biotech Push, says AHF

LOS ANGELES–(BUSINESS WIRE)–#COVID19–A Washington Post investigation has revealed an ambitious effort by China to expand its biotechnology sector significantly, with sometimes controversial research, to keep up with (or overtake) the U.S. and other Western powers while failing to ensure adequate safety measures kept pace. AIDS Healthcare Foundation (AHF) urges China or any nation conducting research … [Read more…]

Rapid Dose Announces Board of Director Changes

BURLINGTON, Ontario–(BUSINESS WIRE)–Rapid Dose Therapeutics Corp. (“RDT” or the “Company”) (CSE: DOSE), a Canadian biotechnology company leveraging an innovative, proprietary oral delivery platform, is announcing changes to its board of directors. Jason Lewis has resigned as a director of the Company. We thank him for his three years of service as a director. Mr. Lewis … [Read more…]

Two Alabama Teens Receive National Recognition for Helping Create & Pass Alabama’s First-Ever Period Poverty Law

U.S. Senator Katie Britt (R-Ala.) presented the Engage Woman Award for Non-Profit Leadership to Brooke and Breanna Bennett at Engage’s Remarkable Women Reception and Dinner in Washington, D.C. WASHINGTON–(BUSINESS WIRE)–Brooke and Breanna Bennett, Co-Founders of Women in Training, Inc. (WIT), were recognized on March 28 for their tremendous advocacy work – helping to create and … [Read more…]

Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics

OXFORD, England & MARCY-L’ETOILE, France–(BUSINESS WIRE)–Oxford Nanopore Technologies plc (LSE: ONT) (“Oxford Nanopore”), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics, today announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring … [Read more…]

MiNA Therapeutics Presents Late-Breaking Positive Phase 1b Data for MTL-CEBPA in Combination with an Anti-PD1 Checkpoint Inhibitor at the Annual American Association of Cancer Research (AACR) Meeting

Findings validate clinical proof of mechanism of MTL-CEBPA as a combination therapy in solid tumor cancers Company to initiate out-licensing activities of its immuno-oncology portfolio, including MTL-CEBPA LONDON–(BUSINESS WIRE)–MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, will present positive updated biomarker data from its Phase 1a/b TIMEPOINT study of MTL-CEBPA in combination … [Read more…]

Immune-Onc Therapeutics to Present Encouraging Phase 1 Data for IO-108 at AACR Annual Meeting 2023

– Phase 1 data show encouraging clinical benefit for IO-108 as a monotherapy and when combined with pembrolizumab, suggesting potential to overcome resistance to T-cell checkpoint inhibitors – – Preclinical data for IO-312, a novel bispecific antibody targeting LILRB4 (ILT3) and CD3 (LILRB4 x CD3) will be presented as a late-breaking poster at AACR 2023 … [Read more…]

Epic Sciences Raises $24M in Series G Financing to Continue Funding Commercialization of DefineMBC

Funding will accelerate commercial launch of DefineMBC™ SAN DIEGO–(BUSINESS WIRE)–Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, has completed a $24 million Series G which together with its $43 million Series F financing, totals $67 million raised in the last twelve months. The company will use the capital from this additional … [Read more…]